Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Equity Bottom-Up

<ul>
<li>After sidewards movement over the last 18 months, the counter has outperformed over the last few weeks.</li>
<li>There have been some positive developments regarding trials and partnerships, however, there are still various concerns regarding their existing portfolio and pipeline.</li>
<li>Takeda is still trading at a high absolute and relative valuation, and given its poor track record, we don’t believe the premium can be justified.</li>
</ul>


After sidewards movement over the last 18 months, the counter has outperformed over the last few weeks.
There have been some positive developments regarding trials and partnerships, however, there are still various concerns regarding their existing portfolio and pipeline.
Takeda is still trading at a high absolute and relative valuation, and given its poor track record, we don’t believe the premium can be justified.


Takeda (4502 JP) 2026 Update – We Maintain Our Bearish View!

Takeda Pharmaceutical

Takeda (4502 JP) 2026 Update – We Maintain Our Bearish View!